{"prompt": "['MEIRAGTx', 'Gene Therapy for Achromatopsia (CNGA3)', '1.4', 'Roles and responsibilities', 'Agreements that include detailed roles and responsibilities will be in place between participating sites', 'and MeiraGTx UK Il Ltd.', 'These membership lists are correct at the time of writing; please see terms of reference', 'documentation in the TMF for current lists.', 'Name', 'Affiliation', 'Role and responsibilities', 'University', 'College', \"Chief Investigator, Moorfield's Eye Hospital\", 'London', 'University', 'College', \"Co - Investigator, Moorfields's Eye Hospital\", 'London', 'University', 'College', 'Senior Scientist', 'London', 'MeiraGTx UK II Ltd.', 'Chief Medical Officer', 'MeiraGTx UK II Ltd.', 'Chief Development Officer', 'MeiraGTx UK II Ltd.', 'Senior Director Clinical Operations', 'MeiraGTx UK II Ltd.', 'Clinical Project Manager', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 11 of 68']['MEIRAGTx', 'Gene Therapy for Achromatopsia (CNGA3)', '2', 'Trial Diagram', 'Children with cone dysfuction syndrome consistent with CNGA3 deficiency', 'Genetic screening for CNGA3 by accredited laboratory (before or after', 'Ineligible/', 'consent)', 'unwilling to', 'consent', 'Participant/parent/guardian (and child) given participant information sheet', 'and asked to provide informed consent/assent', 'Screening/baseline tests (genetic testing, health status, physical examination,', 'vital signs, ocular examination, visual acuity, OCT, Full Field Stimulus', 'electrophysiology, pregnancy', 'Oral Steriods prescribed 1 week BEFORE Surgery', 'ATIMP administration surgery (1 of 3 doses)', 'Pregnancy test if applicable', '1 day post-operative follow up', '3 days post-operative follow up', '1 week post-operative follow up', '2 weeks post-operative follow up', '4 weeks post-operative follow up', '6 weeks post-operative follow up', '3 months post-operative follow up', '6 months post-operative follow up', 'Recruitment to Long-term Follow Up Study', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 12 of 68']['MEIRAGTx', 'Gene Therapy for Achromatopsia (CNGA3)', '3', 'Abbreviations', 'AAV', 'Adeno-Associated Virus', 'EudraCT', 'European Clinical Trials', 'Ad', 'Adenovirus', 'Database', 'AE', 'Adverse Event', 'EudraVIGILANCE', 'European database for', 'AF', 'Autofluorescence', 'Pharmacovigilance', 'AO', 'Adaptive Optics', 'FAF', 'Fundus Autofluorescence', 'AR', 'Adverse Reaction', 'FDA', '(US) Food and Drug', 'ATIMP', 'Advanced Therapy', 'Administration', 'Investigational Medicinal', 'FWA', 'Federal Wide Assurance', 'Product', 'GCP', 'Good Clinical Practice', 'ATMP', 'Advanced Therapy', 'GLP', 'Good Laboratory Practice', 'Medicinal Products', 'GMO', 'Genetically Modified', 'Bd', 'Bis die twice daily', 'Organism', 'BIOM', 'Binocular Indirect', 'GMP', 'Good Manufacturing', 'Ophthalmo Microscope', 'Practice', 'CA', 'Competent Authority', 'GMSC', 'Genetic Modification', 'cDNA', 'complementary', 'Safety Committee', 'Deoxyribonucleic Acid', 'GTAC', 'Gene Therapy Advisory', 'CEO', 'Chief Executive Officer', 'Committee', 'cGMP', 'cyclic guanosine', 'hCAR', 'Human Cone Arrestin', 'monophosphate', 'HIPAA', 'Health Insurance', 'CI', 'Chief Investigator', 'Portability and', 'CMT', 'Clinical Management', 'Accountability Act', 'Team', 'HRA', 'Health Research', 'CNGA3', 'Cyclic Nucleotide-Gated', 'Authority', 'cation channel Beta-3', 'HSE', 'Health and Safety', 'CRF', 'Case Report Form', 'Executive', 'CRO', 'Contract Research', 'IB', 'Investigator Brochure', 'Organization', 'ICF', 'Informed Consent Form', 'CTA', 'Clinical Trial', 'ICH', 'International Conference', 'Authorisation', 'on Harmonisation', 'CTIMP', 'Clinical Trial of', 'ISe', 'Inner Segment Ellipsoid', 'Investigational Medicinal', 'SDMC', 'Safety andData', 'Product', 'Monitoring Committee', 'DLE', 'Dose-limiting event', 'IMP', 'Investigational Medicinal', 'DNA', 'Deoxyribonucleic acid', 'Product', 'DSUR', 'Development Safety', 'IMPD', 'Investigational Medicinal', 'Update Report', 'Product Dossier', 'ELISA', 'Enzyme-linked', 'IND', 'Investigational New Drug', 'Immunosorbent Assay', 'IRB', 'Institutional Review', 'ELISPOT', 'Enzyme-linked', 'Board', 'ImmunoSpot Assay', 'ISCEV', 'International Society for', 'EMA', 'European Medicines', 'Clinical Electrophysiology', 'Agency', 'of Vision', 'ERG', 'Electroretinography', 'KEC', 'Kellogg Eye Centre', 'ETDRS', 'Early Treatment Diabetic', 'LCA', 'Leber congenital', 'Retinopathy Study', 'amaurosis', 'EU', 'European Union', 'MHRA', 'Medicines and', 'EUCTD', 'European Clinical Trials', 'Healthcare products', 'Directive', 'Regulatory Agency', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 13 of 68']\n\n###\n\n", "completion": "END"}